First license agreement for ImaginAb with a major Japanese pharmaceutical business
ImaginAb Inc, a market leading global biotechnology company, focused on developing next generation immuno oncology imaging agents and therapeutic radiopharmaceuticals (RPT), today announced the signing of a new significant multi-year, non-exclusive license agreement with Chugai, one of the largest Japanese pharmaceutical businesses.
The agreement will see ImaginAb supply clinical doses of its market leading 89Zr CD8 ImmunoPET technology (89Zr-Df-Crefmirlimab) to Chugai for use in their clinical development program.
ImaginAb will receive license fees and payments for providing ongoing technical, clinical, and regulatory support to enable the successful implementation of its CD8 ImmunoPET technology. No other terms are disclosed
Commenting on the announcement, Ian Wilson, Chief Executive Officer of ImaginAb stated:
“We are delighted to welcome Chugai as a new clinical partner, especially as it is the first Japanese business that we have entered into a clinical supply agreement. We are excited about the benefits 89Zr-df-Crefmirlimab can bring and how it can help Chugai to create innovative treatments. Team ImaginAb looks forward to working closely with Chugai to enable our technology to be used across their clinical program “
“We are very pleased to be partnering with ImaginAb, which has a proven expertise and experience in immune-oncology imaging,” said Dr. Tomoyuki Igawa, Head of Translational Research Division at Chugai. “89Zr-df-Crefmirlimab is a powerful tool to translate the biological state of individuals into actionable insights. I hope that this collaboration will give us valuable insights in understanding what benefits our investigational antibodies may potentially offer to patients.”
Wilson continued “ImaginAb has a clear aim to become the lead in diagnostic and treatment choices, transforming patient care and helping patients live better and healthier lives. Our CD8 ImmunoPET technology enables quicker identification of drug efficacy, potentially reduce the length of trials and allowing new therapies to advance to market quicker. It also removes the need for repeat, painful biopsies. All of which will ultimately transform patient care.
This announcement is just the latest in a number of new non-exclusive license agreements that we have announced this year. It is a clear indication that not only is our technology gaining wider acceptance, but many others also share our vision, and belief in the benefits that our CD8 ImmunoPET technology offers”.